Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
AlloVir, Inc.ALVR-7.610.008.880.49-80.33%-26.44%44.15$2.10$0.23283$9.28

Detail of AlloVir, Inc.

 
CEO
Dr. Diana M. Brainard M.D.
Employees
8
Industry
Biotechnology
Sector
Healthcare
Market cap
$1B

Company details

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

AlloVir, Inc.
ALVR • XNGS • US
$9.28
+8.60 (1,264.71%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$1.22
Margin profit
0.00%
52 week low
$0.38
52 week high
$10.12
50-day simple moving average
$2.48
200-day simple moving average
$2.10
Percent held by insiders
49.12%
Percent held by institutions
41.80%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ALVR +1,264.71%
eps change
ALVR 0.00%